D Capital-invested Ebang Pharmaceutical Listed on NEEQ


Recently, Zhuhai Ebang Pharmaceutical Co., Ltd. (Ebang Pharmaceutical, 833437, invested by JD Capital) was officially listed on the National Equities and Exchange Quotations (NEEQ).

Founded in September 2003, Zhuhai Ebang Pharmaceutical is a high-tech pharmaceutical company engaged in the R&D, production and sales of medicines. Covering an area of over 80,000 square meters, the company is equipped with advanced production and quality management systems in line with the Good Manufacturing Practice (GMP) Standards. Every year, Ebang produces 30 million powder injections, 10 million freeze-dried powder injections and 12 million large-volume injections. It also rolls out high-tech products with intellectual property rights, such as TCMI, antibiotics, products for heart health, etc, among which some branded ones take the leading position domestically, helping to realize the diversification and branding of its products.

Furthermore, Ebang was awarded “Major Special Project Undertaker” by the Ministry of Science and Technology of China and “Major Project Undertaker for Strategic Emerging Enterprises of Zhuhai City”. Based on the entrepreneurship requirement of “high technology and high starting point” as well as the talent concept of “talents revitalize the enterprise”, Ebang has attracted a group of technicians and managerial talents, including postdoctoral talents from the Chinese Academy of Sciences. In addition to creating a qualified research platform for technology and academics, the company also established a complete training system and appropriate career paths for the staff.

As an important part of the national economy, the medical industry is closely related to national welfare and people’s livelihood. Against the background where Chinese economy becomes increasingly powerful, the introduction of supporting measures and the stronger health-care awareness among Chinese people have propelled the capacity enhancement of the chemico-pharmaceutical preparations market and the rapid development of the industry. JD Capital has been attaching great importance to investing in the medical industry and has so far invested 39 medical enterprises and four hospitals. 

JD Capital became Ebang Pharmaceutical’s shareholder in 2010, holding 10% stake before the public transfer. So far, 40 of JD Capital’s investees have been listed on the NEEQ.